Olivier Jarry

About Olivier Jarry

Olivier leverages 35+ years of passion improving health and living standards throughout Western / Eastern Europe, the Americas, India, Asia - delivers top / bottom line growth (P&L up to USD 1.4 billion)- starts new businesses (up to USD 0.8 billion)- concludes M&A transactions (up to USD 1.1 billion, 16+ successful post-merger integrations)- drives large enterprise transformations / turnarounds- innovates with digital technologies- orchestrates strategic planning, strategic marketing, business development (up to USD 6 billion)- raises funds for biotech, medtech (USD 40+ million to date)Boards: • Imagiance LLC (dba 3xBL Enterprises)- Principal• Fit4D – Board Member, Advisor (adherence coaching for people with diabetes)• MergerWorks – Advisor (M&A consulting)• Foundation Ventures – Advisor (investments)• Atlas Advisors – Advisor (investments)• NYU Marketing Committee – Board member (education)• Executive Forum – Board member (prof. association)• AdvaMed Dx – former Board member (prof. association)• AFNOR/ISO – former committee member on Project Management standardizationSpecialties: Organic Growth | Turnarounds | Corporate Mergers & Acquisitions (M&A)| Post-Merger Integration (PMI)| Corporate Strategy | Strategic Planning / Operations Planning / Business Planning | Alliances and Joint-Ventures | Business Development | Start-Ups | Funding | Exit Strategies | Angel Investor / Venture Capital (VC)/ Private Equity (PE)| New Products / launches | New Sales Channels / Markets | Emerging Markets | Bottom-Of-the-Pyramid (\"BOP\")| For-profit | Non-for-profit Boards | Multiple Expansion | Revenue Acceleration | Margin Enhancement | EBITDA Improvement | P&L Responsibility | Global Chief Operating Officer (COO)| International Senior Vice-President (SVP)| Pharmaceuticals (Rx)| Generics (Gx)| Vaccines (Vx)| Medical Devices / Diagnostics (Dx)| Over The Counter medicines (OTC)| Treatment Adherence / Behavior Change (Bx)| FMCG / CPG / Consumer Products | Industrial Products | Electronics / Automation | Fortune 50 | B2C | B2B

Experience

1. Chief Operating Officer

   Advantage Therapeutics Inc

   May 2023 — Present · Vienna, AT

   ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.

Education

• HEC Paris

  Executive MBA, International Business

  2006 — 2008

• NYU Stern School of Business

  EMBA, International Business

  2006 — 2008

• ISAE-SUPAERO

  Master of Engineering - MEng, Defense Systems

  1983 — 1984

• The London School of Economics and Political Science (LSE)

  EMBA, International Business

  2006 — 2008

• CentraleSupélec

  MSc, Aerospace

  1980 — 1983

• TRIUM Global Executive MBA

  Master of Business Administration (M.B.A.), Executive MBA, International Business

  2006 — 2008

Skills

• Licensing
• New Business Development
• Executive Management
• Business Planning
• International Business
• Pharmaceuticals
• Team Management
• Strategic Planning
• Latin America
• Product Management
• Process Improvement
• Strategy
• Organizational Development
• Marketing Research
• Forecasting
• Sales Growth
• Strategic Thinking
• Program Management
• Strategic Sourcing
• Marketing Management
• Market Analysis
• Strategic Partnerships
• Biotechnology
• Corporate Development
• Business Strategy
• Market Research
• Due Diligence
• Change Management
• Cross-Functional Team Leadership
• Management
• Marketing Strategy
• Emerging Markets
• Management Consulting
• Organizational Design
• Joint Ventures
• Healthcare
• Business Development
• Product Launch
• Segmentation
• Pharmaceutical Industry